{"name":"ALK-Abelló A/S","slug":"alk-abell-a-s","ticker":"","exchange":"","domain":"alk.net","description":"","hq":"Hørsholm","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"cardiovascular","drugs":[{"name":"ALK tree AIT 12 DU","genericName":"ALK tree AIT 12 DU","slug":"alk-tree-ait-12-du","indication":"Other","status":"phase_2"},{"name":"AVANZ MITE","genericName":"AVANZ MITE","slug":"avanz-mite","indication":"Other","status":"phase_2"},{"name":"AVANZ Phleum pratense","genericName":"AVANZ Phleum pratense","slug":"avanz-phleum-pratense","indication":"Other","status":"phase_2"},{"name":"ALK HDM tablet","genericName":"ALK HDM tablet","slug":"alk-hdm-tablet","indication":"Other","status":"phase_2"},{"name":"ALK Ragweed Tablet","genericName":"ALK Ragweed Tablet","slug":"alk-ragweed-tablet","indication":"Other","status":"phase_1"},{"name":"ALK tree AIT 0.5 DU","genericName":"ALK tree AIT 0.5 DU","slug":"alk-tree-ait-0-5-du","indication":"Other","status":"phase_2"},{"name":"ALK tree AIT 2 DU","genericName":"ALK tree AIT 2 DU","slug":"alk-tree-ait-2-du","indication":"Other","status":"phase_2"},{"name":"ALK tree AIT 4 DU","genericName":"ALK tree AIT 4 DU","slug":"alk-tree-ait-4-du","indication":"Other","status":"phase_2"},{"name":"AVANZ Cupressus","genericName":"AVANZ Cupressus","slug":"avanz-cupressus","indication":"Other","status":"phase_2"},{"name":"AVANZ Salsola","genericName":"AVANZ Salsola","slug":"avanz-salsola","indication":"Other","status":"phase_2"},{"name":"AVANZ olea","genericName":"AVANZ olea","slug":"avanz-olea","indication":"Other","status":"phase_2"},{"name":"Grazax","genericName":"Grazax","slug":"grazax","indication":"Other","status":"marketed"},{"name":"MK-8237 tablets","genericName":"MK-8237 tablets","slug":"mk-8237-tablets","indication":"Allergic rhinitis and related allergic conditions (Phase 3)","status":"phase_3"},{"name":"Olopatadine 0.1% Rescue Treatment","genericName":"Olopatadine 0.1% Rescue Treatment","slug":"olopatadine-0-1-rescue-treatment","indication":"Allergic conjunctivitis (rescue/acute treatment)","status":"phase_3"},{"name":"Pangramin Plus D. pteronyssinus 100%","genericName":"Pangramin Plus D. pteronyssinus 100%","slug":"pangramin-plus-d-pteronyssinus-100","indication":"Other","status":"marketed"},{"name":"Placebo for SCH 39641","genericName":"Placebo for SCH 39641","slug":"placebo-for-sch-39641","indication":"Other","status":"phase_3"},{"name":"Placebo for SCH 697243","genericName":"Placebo for SCH 697243","slug":"placebo-for-sch-697243","indication":"Other","status":"phase_3"},{"name":"Rescue Medication: Loratadine tablets","genericName":"Rescue Medication: Loratadine tablets","slug":"rescue-medication-loratadine-tablets","indication":"Allergic rhinitis (seasonal and perennial)","status":"phase_3"},{"name":"Rescue Medication: Olopatadine ophthalmic drops","genericName":"Rescue Medication: Olopatadine ophthalmic drops","slug":"rescue-medication-olopatadine-ophthalmic-drops","indication":"Allergic conjunctivitis (itching and redness associated with allergic reactions)","status":"phase_3"},{"name":"Rescue Medication: Self-Injectable Epinephrine","genericName":"Rescue Medication: Self-Injectable Epinephrine","slug":"rescue-medication-self-injectable-epinephrine","indication":"Anaphylaxis (emergency rescue treatment)","status":"phase_3"},{"name":"SQ SLIT-tablet","genericName":"SQ SLIT-tablet","slug":"sq-slit-tablet","indication":"Other","status":"phase_2"},{"name":"Sublingual allergy immunotherapy tablet","genericName":"Sublingual allergy immunotherapy tablet","slug":"sublingual-allergy-immunotherapy-tablet","indication":"Treatment of grass pollen allergy symptoms","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"AIT Tablet","genericName":"AIT Tablet","slug":"ait-tablet","indication":"Allergic rhinitis and/or allergic asthma caused by specific allergens (exact allergen depends on formulation)","status":"marketed"},{"name":"ALK HDM AIT 12 DU","genericName":"ALK HDM AIT 12 DU","slug":"alk-hdm-ait-12-du","indication":"House dust mite allergic rhinitis and/or asthma","status":"phase_3"},{"name":"HDM SLIT-tablet","genericName":"HDM SLIT-tablet","slug":"hdm-slit-tablet","indication":"Allergic rhinitis and/or allergic asthma induced by house dust mite allergen","status":"phase_3"},{"name":"Tree SLIT-tablet","genericName":"Tree SLIT-tablet","slug":"tree-slit-tablet","indication":"Allergic rhinitis and/or allergic asthma caused by tree pollen allergens","status":"phase_3"},{"name":"ALK Grass tablet","genericName":"ALK Grass tablet","slug":"alk-grass-tablet","indication":"Grass pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"ALK HDM AIT 6 DU","genericName":"ALK HDM AIT 6 DU","slug":"alk-hdm-ait-6-du","indication":"House dust mite allergic rhinitis and/or asthma","status":"phase_3"},{"name":"Grazax + Aerius","genericName":"Grazax + Aerius","slug":"grazax-aerius","indication":"Grass pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"Grazax-R","genericName":"Grazax-R","slug":"grazax-r","indication":"Grass pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"HDM SLIT-tablet (12 SQ-HDM)","genericName":"HDM SLIT-tablet (12 SQ-HDM)","slug":"hdm-slit-tablet-12-sq-hdm","indication":"House dust mite allergic rhinitis and/or asthma","status":"phase_3"},{"name":"Pangramin SLIT HDM mix.","genericName":"Pangramin SLIT HDM mix.","slug":"pangramin-slit-hdm-mix","indication":"Allergic rhinitis and/or asthma induced by house dust mite allergens","status":"phase_3"},{"name":"SCH 39641","genericName":"SCH 39641","slug":"sch-39641","indication":"Asthma","status":"phase_3"},{"name":"subcutaneous immunotherapy","genericName":"subcutaneous immunotherapy","slug":"subcutaneous-immunotherapy","indication":"Allergic rhinitis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ALK tree AIT 1 DU","genericName":"ALK tree AIT 1 DU","slug":"alk-tree-ait-1-du","indication":"Non-small cell lung cancer with ALK rearrangement","status":"phase_2"},{"name":"ALK tree AIT 7 DU","genericName":"ALK tree AIT 7 DU","slug":"alk-tree-ait-7-du","indication":"Non-small cell lung cancer with ALK rearrangement","status":"phase_2"},{"name":"SCH 697243","genericName":"SCH 697243","slug":"sch-697243","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Placebo SLIT-tablet","genericName":"Placebo SLIT-tablet","slug":"placebo-slit-tablet","indication":"Placebo control in phase 3 clinical trials for sublingual immunotherapy","status":"phase_3"}]}],"pipeline":[{"name":"AIT Tablet","genericName":"AIT Tablet","slug":"ait-tablet","phase":"marketed","mechanism":"AIT Tablet is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through gradual oral exposure.","indications":["Allergic rhinitis and/or allergic asthma caused by specific allergens (exact allergen depends on formulation)"],"catalyst":""},{"name":"ALK HDM AIT 12 DU","genericName":"ALK HDM AIT 12 DU","slug":"alk-hdm-ait-12-du","phase":"phase_3","mechanism":"ALK HDM AIT 12 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration.","indications":["House dust mite allergic rhinitis and/or asthma"],"catalyst":""},{"name":"ALK tree AIT 1 DU","genericName":"ALK tree AIT 1 DU","slug":"alk-tree-ait-1-du","phase":"phase_2","mechanism":"ALK tree AIT 1 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein.","indications":["Non-small cell lung cancer with ALK rearrangement"],"catalyst":""},{"name":"ALK tree AIT 12 DU","genericName":"ALK tree AIT 12 DU","slug":"alk-tree-ait-12-du","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVANZ MITE","genericName":"AVANZ MITE","slug":"avanz-mite","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVANZ Phleum pratense","genericName":"AVANZ Phleum pratense","slug":"avanz-phleum-pratense","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HDM SLIT-tablet","genericName":"HDM SLIT-tablet","slug":"hdm-slit-tablet","phase":"phase_3","mechanism":"HDM SLIT-tablet is a sublingual immunotherapy that delivers house dust mite allergen extract to induce immune tolerance and reduce allergic responses.","indications":["Allergic rhinitis and/or allergic asthma induced by house dust mite allergen"],"catalyst":""},{"name":"Tree SLIT-tablet","genericName":"Tree SLIT-tablet","slug":"tree-slit-tablet","phase":"phase_3","mechanism":"Tree SLIT-tablet is a sublingual immunotherapy that desensitizes the immune system to tree pollen allergens by gradually exposing patients to increasing doses of allergen extract.","indications":["Allergic rhinitis and/or allergic asthma caused by tree pollen allergens"],"catalyst":""},{"name":"ALK Grass tablet","genericName":"ALK Grass tablet","slug":"alk-grass-tablet","phase":"phase_3","mechanism":"ALK Grass tablet is an allergen immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure.","indications":["Grass pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"ALK HDM AIT 6 DU","genericName":"ALK HDM AIT 6 DU","slug":"alk-hdm-ait-6-du","phase":"phase_3","mechanism":"ALK HDM AIT 6 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration.","indications":["House dust mite allergic rhinitis and/or asthma"],"catalyst":""},{"name":"ALK HDM tablet","genericName":"ALK HDM tablet","slug":"alk-hdm-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALK Ragweed Tablet","genericName":"ALK Ragweed Tablet","slug":"alk-ragweed-tablet","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALK tree AIT 0.5 DU","genericName":"ALK tree AIT 0.5 DU","slug":"alk-tree-ait-0-5-du","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALK tree AIT 2 DU","genericName":"ALK tree AIT 2 DU","slug":"alk-tree-ait-2-du","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALK tree AIT 4 DU","genericName":"ALK tree AIT 4 DU","slug":"alk-tree-ait-4-du","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALK tree AIT 7 DU","genericName":"ALK tree AIT 7 DU","slug":"alk-tree-ait-7-du","phase":"phase_2","mechanism":"ALK tree AIT 7 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein.","indications":["Non-small cell lung cancer with ALK rearrangement"],"catalyst":""},{"name":"AVANZ Cupressus","genericName":"AVANZ Cupressus","slug":"avanz-cupressus","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVANZ Salsola","genericName":"AVANZ Salsola","slug":"avanz-salsola","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVANZ olea","genericName":"AVANZ olea","slug":"avanz-olea","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Grazax","genericName":"Grazax","slug":"grazax","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Grazax + Aerius","genericName":"Grazax + Aerius","slug":"grazax-aerius","phase":"phase_3","mechanism":"Grazax is a sublingual immunotherapy tablet that desensitizes the immune system to grass pollen allergens, while Aerius (desloratadine) is an antihistamine that blocks histamine receptors to reduce allergic symptoms.","indications":["Grass pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"Grazax-R","genericName":"Grazax-R","slug":"grazax-r","phase":"phase_3","mechanism":"Grazax-R is an oral immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure under the tongue.","indications":["Grass pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"HDM SLIT-tablet (12 SQ-HDM)","genericName":"HDM SLIT-tablet (12 SQ-HDM)","slug":"hdm-slit-tablet-12-sq-hdm","phase":"phase_3","mechanism":"HDM SLIT-tablet delivers house dust mite allergen extract sublingually to induce immune tolerance through oral mucosal sensitization.","indications":["House dust mite allergic rhinitis and/or asthma"],"catalyst":""},{"name":"MK-8237 tablets","genericName":"MK-8237 tablets","slug":"mk-8237-tablets","phase":"phase_3","mechanism":"MK-8237 is an oral immunotherapeutic agent designed to modulate immune responses, likely through toll-like receptor (TLR) signaling or related innate immune pathways.","indications":["Allergic rhinitis and related allergic conditions (Phase 3)"],"catalyst":""},{"name":"Olopatadine 0.1% Rescue Treatment","genericName":"Olopatadine 0.1% Rescue Treatment","slug":"olopatadine-0-1-rescue-treatment","phase":"phase_3","mechanism":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye.","indications":["Allergic conjunctivitis (rescue/acute treatment)"],"catalyst":""},{"name":"Pangramin Plus D. pteronyssinus 100%","genericName":"Pangramin Plus D. pteronyssinus 100%","slug":"pangramin-plus-d-pteronyssinus-100","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Pangramin SLIT HDM mix.","genericName":"Pangramin SLIT HDM mix.","slug":"pangramin-slit-hdm-mix","phase":"phase_3","mechanism":"Pangramin SLIT HDM mix is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through repeated exposure to gradually increasing doses.","indications":["Allergic rhinitis and/or asthma induced by house dust mite allergens"],"catalyst":""},{"name":"Placebo SLIT-tablet","genericName":"Placebo SLIT-tablet","slug":"placebo-slit-tablet","phase":"phase_3","mechanism":"A placebo sublingual immunotherapy tablet designed to assess efficacy and safety in phase 3 trials by delivering no active therapeutic agent.","indications":["Placebo control in phase 3 clinical trials for sublingual immunotherapy"],"catalyst":""},{"name":"Placebo for SCH 39641","genericName":"Placebo for SCH 39641","slug":"placebo-for-sch-39641","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo for SCH 697243","genericName":"Placebo for SCH 697243","slug":"placebo-for-sch-697243","phase":"phase_3","mechanism":"Placebos do not have an active pharmacological mechanism; they are used as controls in clinical trials.","indications":[],"catalyst":""},{"name":"Rescue Medication: Loratadine tablets","genericName":"Rescue Medication: Loratadine tablets","slug":"rescue-medication-loratadine-tablets","phase":"phase_3","mechanism":"Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria"],"catalyst":""},{"name":"Rescue Medication: Olopatadine ophthalmic drops","genericName":"Rescue Medication: Olopatadine ophthalmic drops","slug":"rescue-medication-olopatadine-ophthalmic-drops","phase":"phase_3","mechanism":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye.","indications":["Allergic conjunctivitis (itching and redness associated with allergic reactions)"],"catalyst":""},{"name":"Rescue Medication: Self-Injectable Epinephrine","genericName":"Rescue Medication: Self-Injectable Epinephrine","slug":"rescue-medication-self-injectable-epinephrine","phase":"phase_3","mechanism":"Epinephrine is a sympathomimetic amine that binds to alpha and beta adrenergic receptors to rapidly reverse the symptoms of anaphylaxis by increasing blood pressure, improving airway patency, and reducing allergic mediator release.","indications":["Anaphylaxis (emergency rescue treatment)","Severe allergic reactions"],"catalyst":""},{"name":"SCH 39641","genericName":"SCH 39641","slug":"sch-39641","phase":"phase_3","mechanism":"SCH 39641 is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.","indications":["Asthma","Allergic rhinitis"],"catalyst":""},{"name":"SCH 697243","genericName":"SCH 697243","slug":"sch-697243","phase":"phase_3","mechanism":"SCH 697243 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"SQ SLIT-tablet","genericName":"SQ SLIT-tablet","slug":"sq-slit-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sublingual allergy immunotherapy tablet","genericName":"Sublingual allergy immunotherapy tablet","slug":"sublingual-allergy-immunotherapy-tablet","phase":"phase_3","mechanism":"Sublingual allergy immunotherapy tablets work by exposing the body to small amounts of an allergen to build up tolerance and reduce symptoms.","indications":["Treatment of grass pollen allergy symptoms"],"catalyst":""},{"name":"subcutaneous immunotherapy","genericName":"subcutaneous immunotherapy","slug":"subcutaneous-immunotherapy","phase":"phase_3","mechanism":"Subcutaneous immunotherapy involves administering allergens or allergen extracts under the skin to build tolerance and reduce allergic reactions.","indications":["Allergic rhinitis","Allergic asthma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"pipeline","source":"The Manila Times","summary":"Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby - The Manila Times","headline":"Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPejdSVXNnSDZFeUdWanMycngzeGttbXY2VFlvWXlsVjRpdHJTX1pJejZZMFlJYjFXQUJLcGVmel92bUo5NWFKM2pETW1iZDlBUGtXYXRZWmtJVHpna2NpRHdCdTBYanRpVUloLXM5bUVDelRfeXpiQ0pNOUdJUDIxM1h4RlNNTTdlOHhfSV9jVF9XQmZtS2NlQ25lREcwdWRrc3g1U3BFdS1iSzhSeVpVWlhxZERlMFNGX2R1MHFn?oc=5","date":"2026-04-02","type":"regulatory","source":"respiratory-therapy.com","summary":"UK Approves EURneffy Nasal Spray - respiratory-therapy.com","headline":"UK Approves EURneffy Nasal Spray - respiratory","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcGlWZXJJblI0Yi1HQTRvdHp5WGpINzZSSUVwNkIxN2RKVEVZczV6N1lkNzBrM0NINFg2bWNqVWdOLWxuT3laWlRxV3NKTUZ4d04zU2RnMlhCbm1SclYtdE5jTlA0ZUFUWFFmLWdzaXdaaHZ0cGJkZVd4emxDbHNCMlJZaU9oX2VRMHN1RFRpX3dQaHVyZGxFRFlhWDRlb1RFLTl4S1RJSlFRSkNrOUxQWUw4eDhfUFp6N2RiMw?oc=5","date":"2026-03-11","type":"pipeline","source":"seekingalpha.com","summary":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - seekingalpha.com","headline":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQOXJDc1FSYmV2bU84N21JeGg5Nm9EVjNTWHF5WjN4XzEzVzhuZUNxSENzdld1V2VuN3RxZ3hNcVhDNUMxazVuYWNDeGVoOEFuOE1uOGd4RVF0X05xMHo4TGxhYUdXRXljZ0NhSlpDTTRha0puRzd1U1hPZFBvTmdiWWwxajIzOWdsbXZ5eTMxcGIzQ3dmWlJTc1VJc3JsVm9PV0gxYkw5WnRGcnVhdFgyQ3g3Z3pESGZ0dGhmcmd1ZDdVMlBiWEFmWHctRDNZYVl3RERlOGRkQ0RBMEdhNk5RVE50OHQ1V3JIVF9nLWFlVi0zQUpnamJzbWQ1QmhuSjZOVlpiQURrU21LM1FGa1dKWTlWVGFqYnROV3FpeVhzTzVPM1hPeGJNRTdWNGFSZEVFUUpVLUpvZkwyZzRMUEd3YzB5Sk4?oc=5","date":"2025-12-01","type":"regulatory","source":"Business Wire","summary":"Human Vaccines Strategic Business Analysis Report 2025: Emergence of New Pathogens Drives Demand for Novel Vaccines - Global Forecast to 2030 - ResearchAndMarkets.com - Business Wire","headline":"Human Vaccines Strategic Business Analysis Report 2025: Emergence of New Pathogens Drives Demand for Novel Vaccines - Gl","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st","headline":"ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxObzRFdjVVNUNlQWtIMXZOQVY5RjQ4VTR4aUEyV3NSRTFteV9jcS1aanZNc241MklRSGhONFhQYmo0cms4WXYwZEJPZXFMcWh3b2lPaTg4dU1WMEV5SW95SU4zRHF3TUNZVDBBaVltMWt2YUdwQjZ5NFZHTmM5bmZsWC1RNHpqMkZNamxXN2paQjBpS0JNQThmS0VHaHB2YW1WblpLZlBfYndXTE1YRlZj?oc=5","date":"2025-07-21","type":"regulatory","source":"European Pharmaceutical Review","summary":"MHRA approves needle-free allergy drug alternative - European Pharmaceutical Review","headline":"MHRA approves needle-free allergy drug alternative","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQMVg5NkV5cUJZMnpERi1nLXJWQ0Y2ekw5TmN1VjNZTFFJd2FvSHJZSEJhY0QwYTJFSDZuN0Y1UFJJMFgzdHZjWVRHbHFwRk5OQkt2NDhsVVZLYmtxR082LXl1enEwQmhNVkFZT0RyZHhfNG0td2dZSnZ0eGZmRkxWVkVZYnFhbnQ4Yk1TanFxZjFpWFdJUTE5RE15ZlpreUFjV1c1bw?oc=5","date":"2025-05-07","type":"pipeline","source":"Allergic Living","summary":"Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living","headline":"Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOTRCVDRSXzFRVVp3OERmSTFiT1QxUWkxYVFtMjJycjk5VkJKYS00Z09QaDNSd0NDc081c3gwYzRSblVNeUJtcVFfWVZOczB5X3ZtaG01VVpuN1lLQTUzYUZkaG1sWmVqSWtKb1E1cjlQSTFBUTZsM0Z4QjJlRzBhNXRyU0xoSk5VVzhaZlhiWXJGQQ?oc=5","date":"2025-05-02","type":"deal","source":"Yahoo Finance","summary":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - Yahoo ","headline":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Rea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQSE05MWRiVzlwdW5IRWEwSkk0bTdPbjRPR2czRmRwdmd3ZHpseC1jS01keWU3X2ozcUt0a3BuZGIwWmRaME5VRXRNR1phZnkyaGNmTlZ1VHBObTBFODk3anhRanluR3pIYTFZdV9QSHRpTWVvT2d1c3hfUmpwM0RBYk9xUGZtLUtKS3lucmVBMzVkX0RDa2lScVMtUE9WSjBBU2RDdms5OHdlbFhqYWtvLXhpZnBpbHBaU282ZUFyNGdzVXVnc1VVQlZkTFdjQkplaElGeVlTUHpaQQ?oc=5","date":"2025-01-06","type":"regulatory","source":"Quiver Quantitative","summary":"ARS Pharmaceuticals Files for Approval of neffy® (Epinephrine Nasal Spray) 2 mg in Canada and the UK - Quiver Quantitative","headline":"ARS Pharmaceuticals Files for Approval of neffy® (Epinephrine Nasal Spray) 2 mg in Canada and the UK","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPWF82QlZZS2R2U1ROSWJuZ0FRZTJiNmpLekc3REZXOUNpRU1kZGIxOWN5Tmh4LVBUekVmNjJuT2dMU3NfNHZTb2JRMW5mRnBtMjh0VHQyTDZ1aElmRXNTYW95R3hnYzk4X0E3SEpvUktKclhidHRBTTFrUVJTYWppZjJJdFZhc1pFOGo2cHNzSS10VVhFMmd5c1VoU3V2Z0lQR2QtSHU2TjlWY2duQjVEc2h3U1RrYy16S1N6RkVfM2s?oc=5","date":"2024-12-16","type":"pipeline","source":"Bloomberg.com","summary":"Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor - Bloomberg.com","headline":"Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxOcWhNZUJwa0ZHTV83emV6VGkwWjRJeVNkY2xnVFM1T3p4b2RsT0J5TVlzc2t0RTBUOUx4NDlZSnlxTUpBYUF1VHhhZWN5TVdNQ2tJQ0EweVZzdWlPNk12R2hRYVI0WnpTZk9VT043Q1NVblZGc1VyMTZFVWpkYVZ5THZxRkI2T2ZZY0hzU3VHOGdGczVvY0N6VGZBbk44cWxMZFlVbldubXRBdFA2TnBiUGc4STdDWmFIT3V4dXhRU0NvUS1yeXhlLXZGQzlCMkZWRFdxemFucGpTTlZLQnA4TDljRnVheWQ3V1Q2di1rbGFQRlR3clN6R1J5ZXE2eFdNR1lxQWNqYS1LTHdSSVdCUm14cWFYREYtbERKOWVIeG5UZWhwT0J3ai1MdkF6aGNtcmJ1eEEtTVlGWHFGRUdWaWJFQkh3WkRFRnF0WUZTeTFybEtNMm45b0dLQ0g?oc=5","date":"2024-11-11","type":"pipeline","source":"GlobeNewswire","summary":"ARS Pharmaceuticals Announces Exclusive Agreement with - GlobeNewswire","headline":"ARS Pharmaceuticals Announces Exclusive Agreement with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPd0RmQW0yTGtLTTJsX3BvVU1IRzhoUWFId0FRbXdMQ1d6YjE1ajh4ZnFjbG5pb1JkM1NWTmtfVnNSOTVCNGllX1RDejBpOTJQcGd6RW5NTkY1RHhEUEo5VHE0SHBNeWxxQ0pmaGRXMHJuNUpGdWpMY2ZrelZTWWxPcEtoOA?oc=5","date":"2023-07-05","type":"pipeline","source":"BioCentury","summary":"The secret behind Denmark’s success - BioCentury","headline":"The secret behind Denmark’s success","sentiment":"neutral"}],"patents":[],"drugCount":38,"phaseCounts":{"marketed":3,"phase_3":21,"phase_2":13,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}